Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I study of Irinotecan tablet for treatment of advanced solid tumours

Trial Profile

A Phase I study of Irinotecan tablet for treatment of advanced solid tumours

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Capecitabine (Primary) ; Irinotecan (Primary)
  • Indications Cholangiocarcinoma; Colon cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Nov 2018 According to an Ascelia Pharma media release, results from this trial have been newly published and are available on pubmed.gov titled "Oral administration of irinotecan in patients with solid tumours: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics".
    • 13 Nov 2018 Results presented in the Ascelia Pharma media release.
    • 23 Oct 2018 Results presented in the Ascelia Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top